{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T04:08:25Z","timestamp":1773115705201,"version":"3.50.1"},"publisher-location":"Cham","reference-count":148,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030740450","type":"print"},{"value":"9783030740467","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-3-030-74046-7_4","type":"book-chapter","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T18:02:39Z","timestamp":1630087359000},"page":"31-48","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The NGF Metabolic Pathway: New Opportunities for Biomarker Research and Drug Target Discovery"],"prefix":"10.1007","author":[{"given":"Rowan","family":"Pentz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Florencia","family":"Iulita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,28]]},"reference":[{"key":"4_CR1","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1161\/01.STR.0000127420.10990.76","volume":"35","author":"JC Adair","year":"2004","unstructured":"Adair JC et al (2004) Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease. Stroke 35:e159\u2013e162","journal-title":"Stroke"},{"key":"4_CR2","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3233\/JAD-180241","volume":"64","author":"H Akhter","year":"2018","unstructured":"Akhter H et al (2018) A small molecule inhibitor of plasminogen activator inhibitor-1 reduces brain amyloid-\u03b2 load and improves memory in an animal model of alzheimer\u2019s disease. J Alzheimers Dis 64:447\u2013457","journal-title":"J Alzheimers Dis"},{"key":"4_CR3","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1523\/JNEUROSCI.1144-11.2012","volume":"32","author":"S Allard","year":"2012","unstructured":"Allard S et al (2012a) Impact of the NGF maturation and degradation pathway on the cortical cholinergic system phenotype. J Neurosci 32:2002\u20132012","journal-title":"J Neurosci"},{"key":"4_CR4","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1523\/JNEUROSCI.1144-11.2012","volume":"32","author":"S Allard","year":"2012","unstructured":"Allard S et al (2012b) Impact of the NGF maturation and degradation pathway on the cortical cholinergic system phenotype. J Neurosci 32:2002\u20132012","journal-title":"J Neurosci"},{"key":"4_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.neurobiolaging.2018.03.002","volume":"67","author":"S Allard","year":"2018","unstructured":"Allard S et al (2018a) Compromise of cortical proNGF maturation causes selective retrograde atrophy in cholinergic nucleus basalis neurons. Neurobiol Aging 67:10\u201320","journal-title":"Neurobiol Aging"},{"key":"4_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.neurobiolaging.2018.03.002","volume":"67","author":"S Allard","year":"2018","unstructured":"Allard S et al (2018b) Compromise of cortical proNGF maturation causes selective retrograde atrophy in cholinergic nucleus basalis neurons. Neurobiol Aging 67:10\u201320","journal-title":"Neurobiol Aging"},{"key":"4_CR7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1001\/jamaneurol.2019.3606","volume":"77","author":"FSH Al-Shaikh","year":"2020","unstructured":"Al-Shaikh FSH et al (2020) Selective vulnerability of the nucleus basalis of Meynert among neuropathologic subtypes of Alzheimer disease. JAMA Neurol 77:225\u2013233","journal-title":"JAMA Neurol"},{"key":"4_CR8","doi-asserted-by":"publisher","first-page":"7910","DOI":"10.1523\/JNEUROSCI.16-24-07910.1996","volume":"16","author":"JR Backstrom","year":"1996","unstructured":"Backstrom JR et al (1996) Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-\u03b2 peptide (1\u201340). J Neurosci 16:7910\u20137919","journal-title":"J Neurosci"},{"key":"4_CR9","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1126\/science.7046051","volume":"217","author":"RT Bartus","year":"1982","unstructured":"Bartus RT et al (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408\u2013414","journal-title":"Science"},{"key":"4_CR10","volume":"6","author":"JS Birks","year":"2018","unstructured":"Birks JS, Harvey RJ (2018) Donepezil for dementia due to Alzheimer\u2019s disease. Cochrane Database Syst Rev 6:CD001190","journal-title":"Cochrane Database Syst Rev"},{"key":"4_CR11","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.expneurol.2008.03.004","volume":"211","author":"KM Bishop","year":"2008","unstructured":"Bishop KM et al (2008) Therapeutic potential of CERE-110 (AAV2-NGF): targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons. Exp Neurol 211:574\u2013584","journal-title":"Exp Neurol"},{"key":"4_CR12","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/joim.12816","volume":"284","author":"K Blennow","year":"2018","unstructured":"Blennow K, Zetterberg H (2018) Biomarkers for Alzheimer\u2019s disease: current status and prospects for the future. J Intern Med 284:643\u2013663","journal-title":"J Intern Med"},{"key":"4_CR13","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.jalz.2018.03.005","volume":"14","author":"R Brookmeyer","year":"2018","unstructured":"Brookmeyer R, Abdalla N (2018) Estimation of lifetime risks of Alzheimer\u2019s disease dementia using biomarkers for preclinical disease. Alzheimers Dement 14:981\u2013988","journal-title":"Alzheimers Dement"},{"key":"4_CR14","doi-asserted-by":"publisher","first-page":"6735","DOI":"10.1073\/pnas.0510645103","volume":"103","author":"MA Bruno","year":"2006","unstructured":"Bruno MA, Cuello AC (2006) Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. Proc Natl Acad Sci 103:6735\u20136740","journal-title":"Proc Natl Acad Sci"},{"key":"4_CR15","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1097\/NEN.0b013e3181aed9e6","volume":"68","author":"MA Bruno","year":"2009","unstructured":"Bruno MA et al (2009a) Amyloid \u03b2-induced nerve growth factor dysmetabolism in Alzheimer disease. J Neuropathol Exp Neurol 68:857\u2013869","journal-title":"J Neuropathol Exp Neurol"},{"key":"4_CR16","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1097\/NEN.0b013e3181c22569","volume":"68","author":"MA Bruno","year":"2009","unstructured":"Bruno MA et al (2009b) Increased matrix Metalloproteinase-9 activity in mild cognitive impairment. J Neuropathol Exp Neurol 68:1309","journal-title":"J Neuropathol Exp Neurol"},{"key":"4_CR17","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.neuron.2006.01.020","volume":"49","author":"A Caccamo","year":"2006","unstructured":"Caccamo A et al (2006) M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 49:671\u2013682","journal-title":"Neuron"},{"key":"4_CR18","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/S1000-1948(08)60017-9","volume":"22","author":"Z-Y Cai","year":"2007","unstructured":"Cai Z-Y et al (2007) Serum level of MMP-2, MMP-9 and ox-LDL in Alzheimer\u2019s disease with hyperlipoidemia. J Med Coll PLA 22:352\u2013356","journal-title":"J Med Coll PLA"},{"key":"4_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017321","volume":"6","author":"S Capsoni","year":"2011","unstructured":"Capsoni S et al (2011) Taking pain out of NGF: a \u201cpainless\u201d NGF mutant, linked to hereditary sensory autonomic neuropathy type V, with full neurotrophic activity. PloS One 6:e17321","journal-title":"PloS One"},{"key":"4_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037555","volume":"7","author":"S Capsoni","year":"2012","unstructured":"Capsoni S et al (2012) Intranasal \u201cpainless\u201d human nerve growth factors slows amyloid neurodegeneration and prevents memory deficits in app X PS1 mice. PLoS One 7:e37555","journal-title":"PLoS One"},{"key":"4_CR21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/brain\/aww271","volume":"140","author":"S Capsoni","year":"2017","unstructured":"Capsoni S et al (2017) The chemokine CXCL12 mediates the anti-amyloidogenic action of painless human nerve growth factor. Brain 140:201\u2013217","journal-title":"Brain"},{"key":"4_CR22","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1089\/hum.2019.367","volume":"31","author":"MJ Castle","year":"2020","unstructured":"Castle MJ et al (2020) Postmortem analysis in a clinical trial of AAV2-NGF gene therapy for Alzheimer\u2019s disease identifies a need for improved vector delivery. Hum Gene Ther 31:415\u2013422","journal-title":"Hum Gene Ther"},{"key":"4_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.phrs.2018.10.028","volume":"139","author":"A Cattaneo","year":"2019","unstructured":"Cattaneo A, Capsoni S (2019) Painless nerve growth factor: a TrkA biased agonist mediating a broad neuroprotection via its actions on microglia cells. Pharmacol Res 139:17\u201325","journal-title":"Pharmacol Res"},{"issue":"12","key":"4_CR24","doi-asserted-by":"publisher","first-page":"e1631","DOI":"10.4088\/JCP.15m10413","volume":"77","author":"E Cavedo","year":"2016","unstructured":"Cavedo E et al (2016) Reduced regional cortical thickness rate of change in donepezil-treated subjects with suspected prodromal Alzheimer\u2019s disease. J Clin Psychiatry 77(12):e1631\u2013e1638","journal-title":"J Clin Psychiatry"},{"key":"4_CR25","doi-asserted-by":"publisher","first-page":"11706","DOI":"10.1038\/s41598-017-09780-3","volume":"7","author":"E Cavedo","year":"2017","unstructured":"Cavedo E et al (2017) Reduced basal forebrain atrophy progression in a randomized donepezil trial in prodromal Alzheimer\u2019s disease. Sci Rep 7:11706","journal-title":"Sci Rep"},{"key":"4_CR26","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/gerona\/61.3.267","volume":"61","author":"JA Claassen","year":"2006","unstructured":"Claassen JA, Jansen RW (2006) Cholinergically mediated augmentation of cerebral perfusion in alzheimer\u2019s disease and related cognitive disorders: the cholinergic\u2013vascular hypothesis. J Gerontol Ser A Biol Med Sci 61:267\u2013271","journal-title":"J Gerontol Ser A Biol Med Sci"},{"key":"4_CR27","doi-asserted-by":"publisher","first-page":"800","DOI":"10.2174\/1567205013666160129095649","volume":"13","author":"S Counts","year":"2016","unstructured":"Counts S et al (2016) Cerebrospinal fluid proNGF: a putative biomarker for early Alzheimer\u2019s disease. Curr Alzheimer Res 13:800\u2013808","journal-title":"Curr Alzheimer Res"},{"key":"4_CR28","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S0079-6123(08)62117-2","volume":"109","author":"AC Cuello","year":"1996","unstructured":"Cuello AC (1996) Effects of trophic factors on the CNS cholinergic phenotype. Prog Brain Res 109:347\u2013358","journal-title":"Prog Brain Res"},{"key":"4_CR29","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2174\/156720507781788774","volume":"4","author":"A Cuello","year":"2007","unstructured":"Cuello A et al (2007) NGF-cholinergic dependency in brain aging, MCI and Alzheimer\u2019s disease. Curr Alzheimer Res 4:351\u2013358","journal-title":"Curr Alzheimer Res"},{"key":"4_CR30","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3389\/fnins.2019.00062","volume":"13","author":"AC Cuello","year":"2019","unstructured":"Cuello AC et al (2019) The brain NGF metabolic pathway in health and in Alzheimer\u2019s pathology. Front Neurosci 13:62","journal-title":"Front Neurosci"},{"key":"4_CR31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0928-4257(98)80011-9","volume":"92","author":"T Debeir","year":"1998","unstructured":"Debeir T et al (1998) TrkA antagonists decrease NGF-induced ChAT activity in vitro and modulate cholinergic synaptic number in vivo. J Physiol Paris 92:205\u2013208","journal-title":"J Physiol Paris"},{"key":"4_CR32","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1073\/pnas.96.7.4067","volume":"96","author":"T Debeir","year":"1999","unstructured":"Debeir T et al (1999a) A nerve growth factor mimetic TrkA antagonist causes withdrawal of cortical cholinergic boutons in the adult rat. Proc Natl Acad Sci 96:4067\u20134072","journal-title":"Proc Natl Acad Sci"},{"key":"4_CR33","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1073\/pnas.96.7.4067","volume":"96","author":"T Debeir","year":"1999","unstructured":"Debeir T et al (1999b) A nerve growth factor mimetic TrkA antagonist causes withdrawal of cortical cholinergic boutons in the adult rat. Proc Natl Acad Sci U S A 96:4067\u20134072","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4_CR34","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1001\/archneur.1974.00490320001001","volume":"30","author":"DA Drachman","year":"1974","unstructured":"Drachman DA, Leavitt J (1974) Human memory and the cholinergic system. A relationship to aging? Arch Neurol 30:113\u2013121","journal-title":"Arch Neurol"},{"key":"4_CR35","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B et al (2014) Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol 13:614\u2013629","journal-title":"Lancet Neurol"},{"key":"4_CR36","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.jalz.2014.10.003","volume":"11","author":"B Dubois","year":"2015","unstructured":"Dubois B et al (2015) Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer\u2019s disease. Alzheimers Dement 11:1041\u20131049","journal-title":"Alzheimers Dement"},{"key":"4_CR37","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1038\/npp.2015.279","volume":"41","author":"A ElAli","year":"2016","unstructured":"ElAli A et al (2016) Tissue-plasminogen activator attenuates Alzheimer\u2019s disease-related pathology development in APPswe\/PS1 mice. Neuropsychopharmacology 41:1297","journal-title":"Neuropsychopharmacology"},{"key":"4_CR38","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3233\/JAD-190426","volume":"70","author":"YH El-Hayek","year":"2019","unstructured":"El-Hayek YH et al (2019) Tip of the iceberg: assessing the global socioeconomic costs of Alzheimer\u2019s disease and related dementias and strategic implications for stakeholders. J Alzheimers Dis 70:323\u2013341","journal-title":"J Alzheimers Dis"},{"key":"4_CR39","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.yexcr.2018.08.007","volume":"371","author":"M Eriksdotter","year":"2018","unstructured":"Eriksdotter M et al (2018) Cerebrospinal fluid from Alzheimer patients affects cell-mediated nerve growth factor production and cell survival in vitro. Exp Cell Res 371:175\u2013184","journal-title":"Exp Cell Res"},{"key":"4_CR40","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1159\/000336051","volume":"33","author":"M Eriksdotter-J\u00f6nhagen","year":"2012","unstructured":"Eriksdotter-J\u00f6nhagen M et al (2012) Encapsulated cell biodelivery of nerve growth factor to the basal forebrain in patients with Alzheimer\u2019s disease. Dement Geriatr Cogn Disord 33:18\u201328","journal-title":"Dement Geriatr Cogn Disord"},{"key":"4_CR41","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13195-016-0195-9","volume":"8","author":"H Eyjolfsdottir","year":"2016","unstructured":"Eyjolfsdottir H et al (2016) Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer\u2019s disease patients: application of a second-generation encapsulated cell biodelivery device. Alzheimers Res Ther 8:30","journal-title":"Alzheimers Res Ther"},{"key":"4_CR42","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/j.1471-4159.2011.07359.x","volume":"118","author":"S Fabbro","year":"2011","unstructured":"Fabbro S et al (2011) Amyloid-beta levels are significantly reduced and spatial memory defects are rescued in a novel neuroserpin-deficient Alzheimer\u2019s disease transgenic mouse model. J Neurochem 118:928\u2013938","journal-title":"J Neurochem"},{"key":"4_CR43","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1006\/mcne.2001.1016","volume":"18","author":"M Fahnestock","year":"2001","unstructured":"Fahnestock M et al (2001) The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer\u2019s disease. Mol Cell Neurosci 18:210\u2013220","journal-title":"Mol Cell Neurosci"},{"key":"4_CR44","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.3233\/JAD-141068","volume":"43","author":"D Ferreira","year":"2015","unstructured":"Ferreira D et al (2015) Brain changes in Alzheimer\u2019s disease patients with implanted encapsulated cells releasing nerve growth factor. J Alzheimers Dis 43:1059\u20131072","journal-title":"J Alzheimers Dis"},{"key":"4_CR45","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0306-4522(95)91510-J","volume":"68","author":"B Figueiredo","year":"1995","unstructured":"Figueiredo B et al (1995) Differential expression of p140trk, p75NGFR and growth-associated phosphoprotein-43 genes in nucleus basalis magnocellularis, thalamus and adjacent cortex following neocortical infarction and nerve growth factor treatment. Neuroscience 68:29\u201345","journal-title":"Neuroscience"},{"key":"4_CR46","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.nurt.2008.05.002","volume":"5","author":"A Fisher","year":"2008","unstructured":"Fisher A (2008) Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer\u2019s disease. Neurotherapeutics 5:433\u2013442","journal-title":"Neurotherapeutics"},{"key":"4_CR47","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/S1474-4422(18)30285-0","volume":"17","author":"J Fortea","year":"2018","unstructured":"Fortea J et al (2018a) Plasma and CSF biomarkers for the diagnosis of Alzheimer\u2019s disease in adults with down syndrome: a cross-sectional study. Lancet Neurol 17:860\u2013869","journal-title":"Lancet Neurol"},{"key":"4_CR48","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/S1474-4422(18)30285-0","volume":"17","author":"J Fortea","year":"2018","unstructured":"Fortea J et al (2018b) Plasma and CSF biomarkers for the diagnosis of Alzheimer\u2019s disease in adults with down syndrome: a cross-sectional study. Lancet Neurol 17:860\u2013869","journal-title":"Lancet Neurol"},{"key":"4_CR49","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1016\/S0140-6736(20)30689-9","volume":"395","author":"J Fortea","year":"2020","unstructured":"Fortea J et al (2020) Clinical and biomarker changes of Alzheimer\u2019s disease in adults with down syndrome: a cross-sectional study. Lancet 395:1988\u20131997","journal-title":"Lancet"},{"key":"4_CR50","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3233\/JAD-2007-12105","volume":"12","author":"E Giacobini","year":"2007","unstructured":"Giacobini E, Becker RE (2007) One hundred years after the discovery of Alzheimer\u2019s disease. A turning point for therapy? J Alzheimers Dis 12:37\u201352","journal-title":"J Alzheimers Dis"},{"key":"4_CR51","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s007020200089","volume":"109","author":"E Giacobini","year":"2002","unstructured":"Giacobini E et al (2002) Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer\u2019s disease by rivastigmine: correlation with cognitive benefit. J Neural Transm 109:1053\u20131065","journal-title":"J Neural Transm"},{"key":"4_CR52","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/cne.903410304","volume":"341","author":"RB Gibbs","year":"1994","unstructured":"Gibbs RB, Pfaff D (1994) In situ hybridization detection of trkA mRNA in brain: distribution, colocalization with p75NGFR and up-regulation by nerve growth factor. J Comp Neurol 341:324\u2013339","journal-title":"J Comp Neurol"},{"key":"4_CR53","doi-asserted-by":"publisher","first-page":"S344","DOI":"10.1016\/j.jalz.2013.09.011","volume":"10","author":"MJ Grothe","year":"2014","unstructured":"Grothe MJ et al (2014) Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects. Alzheimers Dement 10:S344\u2013S353","journal-title":"Alzheimers Dement"},{"key":"4_CR54","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","volume":"333","author":"Group, N. I. o. N. D. S. r.-P. S. S","year":"1995","unstructured":"Group, N. I. o. N. D. S. r.-P. S. S (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581\u20131588","journal-title":"N Engl J Med"},{"key":"4_CR55","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.jalz.2017.11.009","volume":"14","author":"H Hall","year":"2018","unstructured":"Hall H et al (2018) AF710B, an M1\/sigma-1 receptor agonist with long-lasting disease-modifying properties in a transgenic rat model of Alzheimer\u2019s disease. Alzheimers Dement 14:811\u2013823","journal-title":"Alzheimers Dement"},{"key":"4_CR56","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1093\/brain\/awy132","volume":"141","author":"H Hampel","year":"2018","unstructured":"Hampel H et al (2018) The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease. Brain 141:1917\u20131933","journal-title":"Brain"},{"key":"4_CR57","volume":"12","author":"BL Handen","year":"2020","unstructured":"Handen BL et al (2020) The Alzheimer\u2019s biomarker consortium-down syndrome: rationale and methodology. Alzheimers Dement (Amst) 12:e12065","journal-title":"Alzheimers Dement (Amst)"},{"key":"4_CR58","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3233\/JAD-132282","volume":"40","author":"CE Hanzel","year":"2014","unstructured":"Hanzel CE et al (2014a) Analysis of matrix metallo-proteases and the plasminogen system in mild cognitive impairment and Alzheimer\u2019s disease cerebrospinal fluid. J Alzheimers Dis 40:667\u2013678","journal-title":"J Alzheimers Dis"},{"key":"4_CR59","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1016\/j.neurobiolaging.2014.03.026","volume":"35","author":"CE Hanzel","year":"2014","unstructured":"Hanzel CE et al (2014b) Neuronal driven pre-plaque inflammation in a transgenic rat model of Alzheimer\u2019s disease. Neurobiol Aging 35:2249\u20132262","journal-title":"Neurobiol Aging"},{"key":"4_CR60","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S0304-3940(00)01107-1","volume":"286","author":"J-X Hao","year":"2000","unstructured":"Hao J-X et al (2000) Intracerebroventricular infusion of nerve growth factor induces pain-like response in rats. Neurosci Lett 286:208\u2013212","journal-title":"Neurosci Lett"},{"key":"4_CR61","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/npp.2010.104","volume":"36","author":"ME Hasselmo","year":"2011","unstructured":"Hasselmo ME, Sarter M (2011) Modes and models of forebrain cholinergic neuromodulation of cognition. Neuropsychopharmacology 36:52\u201373","journal-title":"Neuropsychopharmacology"},{"key":"4_CR62","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/00019052-200404000-00003","volume":"17","author":"E Head","year":"2004","unstructured":"Head E, Lott IT (2004) Down syndrome and beta-amyloid deposition. Curr Opin Neurol 17:95\u2013100","journal-title":"Curr Opin Neurol"},{"key":"4_CR63","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/412536","volume":"2012","author":"E Head","year":"2012","unstructured":"Head E et al (2012) Aging and down syndrome. Curr Gerontol Geriatr Res 2012:412536","journal-title":"Curr Gerontol Geriatr Res"},{"key":"4_CR64","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1523\/JNEUROSCI.06-08-02155.1986","volume":"6","author":"F Hefti","year":"1986","unstructured":"Hefti F (1986) Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J Neurosci 6:2155\u20132162","journal-title":"J Neurosci"},{"key":"4_CR65","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0304-3940(86)90410-6","volume":"69","author":"F Hefti","year":"1986","unstructured":"Hefti F et al (1986) Localization of nerve growth factor receptors in cholinergic neurons of the human basal forebrain. Neurosci Lett 69:37\u201341","journal-title":"Neurosci Lett"},{"key":"4_CR66","doi-asserted-by":"publisher","first-page":"103420","DOI":"10.1016\/j.mcn.2019.103420","volume":"102","author":"M Hermann","year":"2020","unstructured":"Hermann M et al (2020) Deficits in developmental neurogenesis and dendritic spine maturation in mice lacking the serine protease inhibitor neuroserpin. Mol Cell Neurosci 102:103420","journal-title":"Mol Cell Neurosci"},{"key":"4_CR67","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1212\/WNL.54.10.2009","volume":"54","author":"C Hock","year":"2000","unstructured":"Hock C et al (2000) Increased CSF levels of nerve growth factor in patients with Alzheimer\u2019s disease. Neurology 54:2009\u20132011","journal-title":"Neurology"},{"key":"4_CR68","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/0896-6273(92)90184-F","volume":"9","author":"DM Holtzman","year":"1992","unstructured":"Holtzman DM et al (1992) p140trk mRNA marks NGF-responsive forebrain neurons: evidence that trk gene expression is induced by NGF. Neuron 9:465\u2013478","journal-title":"Neuron"},{"key":"4_CR69","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1017\/S1041610210000827","volume":"22","author":"S Horstmann","year":"2010","unstructured":"Horstmann S et al (2010) Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer\u2019s disease. Int Psychogeriatr 22:966\u2013972","journal-title":"Int Psychogeriatr"},{"key":"4_CR70","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.tips.2014.04.010","volume":"35","author":"MF Iulita","year":"2014","unstructured":"Iulita MF, Cuello AC (2014) Nerve growth factor metabolic dysfunction in Alzheimer\u2019s disease and down syndrome. Trends Pharmacol Sci 35:338\u2013348","journal-title":"Trends Pharmacol Sci"},{"key":"4_CR71","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2174\/1567205012666150921100030","volume":"13","author":"MF Iulita","year":"2016","unstructured":"Iulita MF, Cuello AC (2016) The NGF metabolic pathway in the CNS and its Dysregulation in down syndrome and Alzheimer\u2019s disease. Curr Alzheimer Res 13:53\u201367","journal-title":"Curr Alzheimer Res"},{"issue":"Pt 3","key":"4_CR72","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1093\/brain\/awt372","volume":"137","author":"MF Iulita","year":"2014","unstructured":"Iulita MF et al (2014) Nerve growth factor metabolic dysfunction in Down\u2019s syndrome brains. Brain 137(Pt 3):860\u2013872. https:\/\/doi.org\/10.1093\/brain\/awt372","journal-title":"Brain"},{"issue":"11","key":"4_CR73","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.jalz.2016.05.001","volume":"12","author":"MF Iulita","year":"2016","unstructured":"Iulita MF et al (2016) An inflammatory and trophic disconnect biomarker profile revealed in down syndrome plasma: relation to cognitive decline and longitudinal evaluation. Alzheimers Dement 12(11):1132\u20131148","journal-title":"Alzheimers Dement"},{"key":"4_CR74","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.nbd.2017.08.019","volume":"108","author":"MF Iulita","year":"2017","unstructured":"Iulita MF et al (2017) Differential deregulation of NGF and BDNF neurotrophins in a transgenic rat model of Alzheimer\u2019s disease. Neurobiol Dis 108:307\u2013323","journal-title":"Neurobiol Dis"},{"key":"4_CR75","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3233\/JAD-180970","volume":"67","author":"MF Iulita","year":"2019","unstructured":"Iulita MF et al (2019) Identification and preliminary validation of a plasma profile associated with cognitive decline in dementia and at-risk individuals: a retrospective cohort analysis. J Alzheimers Dis 67:327\u2013341","journal-title":"J Alzheimers Dis"},{"key":"4_CR76","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement 14:535\u2013562","journal-title":"Alzheimers Dement"},{"key":"4_CR77","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S1474-4422(20)30112-5","volume":"19","author":"CR Jack Jr","year":"2020","unstructured":"Jack CR Jr (2020) The transformative potential of plasma phosphorylated tau. Lancet Neurol 19:373\u2013374","journal-title":"Lancet Neurol"},{"key":"4_CR78","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S et al (2020) Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med 26:379\u2013386","journal-title":"Nat Med"},{"key":"4_CR79","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1097\/00002093-200000001-00006","volume":"14","author":"ME J\u00f6nhagen","year":"2000","unstructured":"J\u00f6nhagen ME (2000) Nerve growth factor treatment in dementia. Alzheimer Dis Assoc Disord 14:S31\u2013S38","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"4_CR80","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1159\/000017069","volume":"9","author":"ME J\u00f6nhagen","year":"1998","unstructured":"J\u00f6nhagen ME et al (1998) Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer\u2019s disease. Dement Geriatr Cogn Disord 9:246\u2013257","journal-title":"Dement Geriatr Cogn Disord"},{"key":"4_CR81","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.jalz.2014.11.008","volume":"11","author":"A Karami","year":"2015","unstructured":"Karami A et al (2015) Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer\u2019s disease. Alzheimers Dement 11:1316\u20131328","journal-title":"Alzheimers Dement"},{"key":"4_CR82","first-page":"239","volume":"12","author":"A Karami","year":"2019","unstructured":"Karami A et al (2019) CSF cholinergic index, a new biomeasure of treatment effect in patients with Alzheimer\u2019s disease. Frontiers in molecular. Neuroscience 12:239","journal-title":"Neuroscience"},{"key":"4_CR83","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK et al (2020) Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol 19:422\u2013433","journal-title":"Lancet Neurol"},{"key":"4_CR84","doi-asserted-by":"publisher","first-page":"29268","DOI":"10.1074\/jbc.M600690200","volume":"281","author":"KJ Kinghorn","year":"2006","unstructured":"Kinghorn KJ et al (2006) Neuroserpin binds A\u03b2 and is a neuroprotective component of amyloid plaques in Alzheimer disease. J Biol Chem 281:29268\u201329277","journal-title":"J Biol Chem"},{"key":"4_CR85","doi-asserted-by":"publisher","first-page":"8984","DOI":"10.1523\/JNEUROSCI.17-23-08984.1997","volume":"17","author":"SR Krueger","year":"1997","unstructured":"Krueger SR et al (1997) Expression of neuroserpin, an inhibitor of tissue plasminogen activator, in the developing and adult nervous system of the mouse. J Neurosci 17:8984\u20138996","journal-title":"J Neurosci"},{"key":"4_CR86","unstructured":"Le AP (2011) Regulation of proNGF processing and its effects on p75NTR-mediated cell death following seizure. Rutgers University-Graduate School-Newark"},{"key":"4_CR87","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3233\/JAD-2011-101974","volume":"26","author":"NK-H Lim","year":"2011","unstructured":"Lim NK-H et al (2011) Investigation of matrix metalloproteinases, MMP-2 and MMP-9, in plasma reveals a decrease of MMP-2 in Alzheimer\u2019s disease. J Alzheimers Dis 26:779\u2013786","journal-title":"J Alzheimers Dis"},{"key":"4_CR88","first-page":"209","volume":"39","author":"Z Lin","year":"2006","unstructured":"Lin Z et al (2006) The plasma matrix metalloproteinase-3 increased in patients with Alzheimer\u2019s disease. Chin J Psychiatry 39:209","journal-title":"Chin J Psychiatry"},{"key":"4_CR89","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.neurobiolaging.2009.06.003","volume":"32","author":"R-M Liu","year":"2011","unstructured":"Liu R-M et al (2011) Knockout of plasminogen activator inhibitor 1 gene reduces amyloid beta peptide burden in a mouse model of Alzheimer\u2019s disease. Neurobiol Aging 32:1079\u20131089","journal-title":"Neurobiol Aging"},{"key":"4_CR90","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0197-0186(03)00004-4","volume":"43","author":"S Lorenzl","year":"2003","unstructured":"Lorenzl S et al (2003) Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer\u2019s disease. Neurochem Int 43:191\u2013196","journal-title":"Neurochem Int"},{"key":"4_CR91","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1017\/S1041610207005790","volume":"20","author":"S Lorenzl","year":"2008","unstructured":"Lorenzl S et al (2008) Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia. Int Psychogeriatr 20:67\u201376","journal-title":"Int Psychogeriatr"},{"key":"4_CR92","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41582-018-0132-6","volume":"15","author":"IT Lott","year":"2019","unstructured":"Lott IT, Head E (2019) Dementia in down syndrome: unique insights for Alzheimer disease research. Nat Rev Neurol 15:135\u2013147","journal-title":"Nat Rev Neurol"},{"key":"4_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-020-00620-7","volume":"12","author":"A Machado","year":"2020","unstructured":"Machado A et al (2020) The cholinergic system in subtypes of Alzheimer\u2019s disease: an in vivo longitudinal MRI study. Alzheimers Res Ther 12:1\u201311","journal-title":"Alzheimers Res Ther"},{"key":"4_CR94","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3389\/fnmol.2016.00063","volume":"9","author":"F Malerba","year":"2016","unstructured":"Malerba F et al (2016) NGF and proNGF reciprocal interference in immunoassays: open questions, criticalities, and ways forward. Front Mol Neurosci 9:63","journal-title":"Front Mol Neurosci"},{"key":"4_CR95","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12963-016-0107-z","volume":"14","author":"DG Manuel","year":"2016","unstructured":"Manuel DG et al (2016) Alzheimer\u2019s and other dementias in Canada, 2011 to 2031: a microsimulation population health modeling (POHEM) study of projected prevalence, health burden, health services, and caregiving use. Popul Health Metr 14:37","journal-title":"Popul Health Metr"},{"key":"4_CR96","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.exger.2013.12.001","volume":"50","author":"J Marksteiner","year":"2014","unstructured":"Marksteiner J et al (2014) Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer\u2019s disease and mild cognitive impairment: a pilot-study. Exp Gerontol 50:114\u2013121","journal-title":"Exp Gerontol"},{"key":"4_CR97","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s11064-008-9789-3","volume":"34","author":"S Mart\u00edn-Arag\u00f3n","year":"2009","unstructured":"Mart\u00edn-Arag\u00f3n S et al (2009) Metalloproteinase\u2019s activity and oxidative stress in mild cognitive impairment and Alzheimer\u2019s disease. Neurochem Res 34:373","journal-title":"Neurochem Res"},{"key":"4_CR98","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00702-012-0778-y","volume":"119","author":"A Martorana","year":"2012","unstructured":"Martorana A et al (2012) Plasmin system of Alzheimer\u2019s disease patients: CSF analysis. J Neural Transm 119:763\u2013769","journal-title":"J Neural Transm"},{"key":"4_CR99","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/BF02340121","volume":"15","author":"A Massaro","year":"1994","unstructured":"Massaro A et al (1994) Nerve growth factor (NGF) in cerebrospinal fluid (CSF) from patients with various neurological disorders. Ital J Neurol Sci 15:105\u2013108","journal-title":"Ital J Neurol Sci"},{"key":"4_CR100","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/547153a","volume":"547","author":"E McDade","year":"2017","unstructured":"McDade E, Bateman RJ (2017) Stop Alzheimer\u2019s before it starts. Nature 547:153","journal-title":"Nature"},{"key":"4_CR101","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/jnc.12093","volume":"124","author":"L McKelvey","year":"2013","unstructured":"McKelvey L et al (2013) Nerve growth factor-mediated regulation of pain signalling and proposed new intervention strategies in clinical pain management. J Neurochem 124:276\u2013289","journal-title":"J Neurochem"},{"key":"4_CR102","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/sj.emboj.7600650","volume":"24","author":"MG Medina","year":"2005","unstructured":"Medina MG et al (2005) Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk1\/2 activation. EMBO J 24:1706\u20131716","journal-title":"EMBO J"},{"key":"4_CR103","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.bbadis.2015.10.011","volume":"1862","author":"A Mehra","year":"2016","unstructured":"Mehra A et al (2016) The plasminogen activation system in neuroinflammation. Biochim Biophys Acta (BBA)-molecular basis of disease 1862:395\u2013402","journal-title":"Biochim Biophys Acta (BBA)-molecular basis of disease"},{"key":"4_CR104","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00018-005-5077-4","volume":"63","author":"E Miranda","year":"2006","unstructured":"Miranda E, Lomas D (2006) Neuroserpin: a serpin to think about. Cell Mol Life Sci CMLS 63:709\u2013722","journal-title":"Cell Mol Life Sci CMLS"},{"key":"4_CR105","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.neulet.2009.09.043","volume":"466","author":"R Mlekusch","year":"2009","unstructured":"Mlekusch R, Humpel C (2009) Matrix metalloproteinases-2 and-3 are reduced in cerebrospinal fluid with low beta-amyloid1\u201342 levels. Neurosci Lett 466:135\u2013138","journal-title":"Neurosci Lett"},{"key":"4_CR106","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3233\/JAD-131634","volume":"40","author":"B Mroczko","year":"2014","unstructured":"Mroczko B et al (2014) Concentrations of matrix metalloproteinases and their tissue inhibitors in the cerebrospinal fluid of patients with Alzheimer\u2019s disease. J Alzheimers Dis 40:351\u2013357","journal-title":"J Alzheimers Dis"},{"key":"4_CR107","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1073\/pnas.89.2.569","volume":"89","author":"EJ Mufson","year":"1992","unstructured":"Mufson EJ, Kordower JH (1992) Cortical neurons express nerve growth factor receptors in advanced age and Alzheimer disease. Proc Natl Acad Sci 89:569\u2013573","journal-title":"Proc Natl Acad Sci"},{"key":"4_CR108","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3389\/fnins.2019.00533","volume":"13","author":"EJ Mufson","year":"2019","unstructured":"Mufson EJ et al (2019) Nerve growth factor pathobiology during the progression of Alzheimer\u2019s disease. Front Neurosci 13:533","journal-title":"Front Neurosci"},{"key":"4_CR109","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S1474-4422(11)70156-9","volume":"10","author":"ME Murray","year":"2011","unstructured":"Murray ME et al (2011) Neuropathologically defined subtypes of Alzheimer\u2019s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol 10:785\u2013796","journal-title":"Lancet Neurol"},{"key":"4_CR110","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1212\/01.wnl.0000271077.82508.a0","volume":"69","author":"HM Nielsen","year":"2007","unstructured":"Nielsen HM et al (2007) Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. Neurology 69:1569\u20131579","journal-title":"Neurology"},{"key":"4_CR111","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1126\/science.1411529","volume":"258","author":"RM Nitsch","year":"1992","unstructured":"Nitsch RM et al (1992) Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258:304\u2013307","journal-title":"Science"},{"key":"4_CR112","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.neuropharm.2005.10.013","volume":"50","author":"E Nizri","year":"2006","unstructured":"Nizri E et al (2006) Anti-inflammatory properties of cholinergic up-regulation: a new role for acetylcholinesterase inhibitors. Neuropharmacology 50:540\u2013547","journal-title":"Neuropharmacology"},{"key":"4_CR113","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.neurobiolaging.2013.09.020","volume":"35","author":"SB Oh","year":"2014","unstructured":"Oh SB et al (2014) Tissue plasminogen activator arrests Alzheimer\u2019s disease pathogenesis. Neurobiol Aging 35:511\u2013519","journal-title":"Neurobiol Aging"},{"key":"4_CR114","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/BF02257624","volume":"4","author":"L Olson","year":"1992","unstructured":"Olson L et al (1992) Nerve growth factor affects 11 C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). J Neural Transm\u2013Parkinson\u2019s disease and dementia section 4:79\u201395","journal-title":"J Neural Transm\u2013Parkinson\u2019s disease and dementia section"},{"key":"4_CR115","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1002\/j.1460-2075.1996.tb00657.x","volume":"15","author":"T Osterwalder","year":"1996","unstructured":"Osterwalder T et al (1996) Neuroserpin, an axonally secreted serine protease inhibitor. EMBO J 15:2944\u20132953","journal-title":"EMBO J"},{"key":"4_CR116","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jchemneu.2010.03.005","volume":"40","author":"CR Overk","year":"2010","unstructured":"Overk CR et al (2010) Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer\u2019s disease. J Chem Neuroanat 40:63\u201370","journal-title":"J Chem Neuroanat"},{"key":"4_CR117","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S et al (2020) Discriminative accuracy of plasma Phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324:772\u2013781","journal-title":"JAMA"},{"key":"4_CR118","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1073\/pnas.0708823105","volume":"105","author":"L Park","year":"2008","unstructured":"Park L et al (2008) Key role of tissue plasminogen activator in neurovascular coupling. Proc Natl Acad Sci 105:1073\u20131078","journal-title":"Proc Natl Acad Sci"},{"key":"4_CR119","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/nri1418","volume":"4","author":"WC Parks","year":"2004","unstructured":"Parks WC et al (2004) Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 4:617","journal-title":"Nat Rev Immunol"},{"key":"4_CR500","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.neulet.2015.04.014","volume":"595","author":"M Peng","year":"2015","unstructured":"Peng M et al (2015) Plasma gelsolin and matrix metalloproteinase 3 as potential biomarkers for Alzheimer disease. Neurosci Lett 595:116\u2013121","journal-title":"Neurosci Lett"},{"key":"4_CR120","doi-asserted-by":"crossref","unstructured":"Pentz R et al (2020) The human brain NGF metabolic pathway is impaired in the pre-clinical and clinical continuum of Alzheimers disease. Mol Psych 1\u201315","DOI":"10.1038\/s41380-020-0797-2"},{"key":"4_CR122","doi-asserted-by":"crossref","unstructured":"Pentz R et al (2021a) Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer\u2019s disease: a paired CSF and plasma study. Alzheimers Dement 17(4):605\u2013617","DOI":"10.1002\/alz.12229"},{"key":"4_CR123","doi-asserted-by":"crossref","unstructured":"Pentz R et al (2021b) A new role for matrix metalloproteinase-3 in the NGF metabolic pathway: proteolysis of mature NGF and sex-specific differences in the continuum of Alzheimer\u2019s pathology. Neurobiol Dis 148:105150","DOI":"10.1016\/j.nbd.2020.105150"},{"key":"4_CR124","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.cbi.2009.11.018","volume":"187","author":"G Pepeu","year":"2010","unstructured":"Pepeu G, Giovannini MG (2010) Cholinesterase inhibitors and memory. Chem Biol Interact 187:403\u2013408","journal-title":"Chem Biol Interact"},{"key":"4_CR125","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jalz.2013.09.004","volume":"10","author":"MS Rafii","year":"2014","unstructured":"Rafii MS et al (2014) A phase 1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer\u2019s disease. Alzheimers Dement 10:571\u2013581","journal-title":"Alzheimers Dement"},{"key":"4_CR126","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2018.0233","volume":"75","author":"MS Rafii","year":"2018","unstructured":"Rafii MS et al (2018) Adeno-associated viral vector (serotype 2)\u2013nerve growth factor for patients with alzheimer disease: a randomized clinical trial. JAMA Neurol 75:834\u2013841","journal-title":"JAMA Neurol"},{"key":"4_CR127","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/brain\/awx356","volume":"141","author":"N Richter","year":"2018","unstructured":"Richter N et al (2018) Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer\u2019s disease. Brain 141:903\u2013915","journal-title":"Brain"},{"key":"4_CR128","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1001\/jamaneurol.2016.0580","volume":"73","author":"SL Risacher","year":"2016","unstructured":"Risacher SL et al (2016) Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol 73:721\u2013732","journal-title":"JAMA Neurol"},{"key":"4_CR129","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.ab.2004.10.052","volume":"338","author":"D Rouy","year":"2005","unstructured":"Rouy D et al (2005) Plasma storage at\u2212 80 C does not protect matrix metalloproteinase-9 from degradation. Anal Biochem 338:294\u2013298","journal-title":"Anal Biochem"},{"key":"4_CR130","doi-asserted-by":"publisher","first-page":"13249","DOI":"10.1038\/ncomms13249","volume":"7","author":"TW Schmitz","year":"2016","unstructured":"Schmitz TW et al (2016) Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer\u2019s pathology. Nat Commun 7:13249","journal-title":"Nat Commun"},{"key":"4_CR131","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.celrep.2018.06.001","volume":"24","author":"TW Schmitz","year":"2018","unstructured":"Schmitz TW et al (2018) Longitudinal Alzheimer\u2019s degeneration reflects the spatial topography of cholinergic basal forebrain projections. Cell Rep 24:38\u201346","journal-title":"Cell Rep"},{"key":"4_CR132","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1476-5381.2010.00894.x","volume":"161","author":"H Shen","year":"2010","unstructured":"Shen H et al (2010) Neuroprotection by donepezil against glutamate excitotoxicity involves stimulation of \u03b17 nicotinic receptors and internalization of NMDA receptors. Br J Pharmacol 161:127\u2013139","journal-title":"Br J Pharmacol"},{"key":"4_CR133","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1440-1819.2010.02074.x","volume":"64","author":"Y Shi","year":"2010","unstructured":"Shi Y et al (2010) Plasma BDNF and tPA are associated with late-onset geriatric depression. Psychiatry Clin Neurosci 64:249\u2013254","journal-title":"Psychiatry Clin Neurosci"},{"key":"4_CR134","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1523\/JNEUROSCI.22-09-03352.2002","volume":"22","author":"C-J Siao","year":"2002","unstructured":"Siao C-J, Tsirka SE (2002) Tissue plasminogen activator mediates microglial activation via its finger domain through annexin II. J Neurosci 22:3352\u20133358","journal-title":"J Neurosci"},{"key":"4_CR135","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/alzrt44","volume":"2","author":"E Stomrud","year":"2010","unstructured":"Stomrud E et al (2010) Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther 2:20","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"4_CR136","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/0006-8993(92)91541-L","volume":"596","author":"AL Svensson","year":"1992","unstructured":"Svensson AL et al (1992) Characterization of muscarinic receptor subtypes in Alzheimer and control brain cortices by selective muscarinic antagonists. Brain Res 596:142\u2013148","journal-title":"Brain Res"},{"key":"4_CR137","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen EH et al (2020) Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat Med 26:387\u2013397","journal-title":"Nat Med"},{"key":"4_CR138","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.3233\/JAD-180752","volume":"66","author":"G Tuna","year":"2018","unstructured":"Tuna G et al (2018) Evaluation of matrix Metalloproteinase-2 (MMP-2) and-9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in plasma from patients with neurodegenerative dementia. J Alzheimers Dis 66:1265\u20131273","journal-title":"J Alzheimers Dis"},{"key":"4_CR139","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1523\/JNEUROSCI.10-11-03604.1990","volume":"10","author":"MH Tuszynski","year":"1990","unstructured":"Tuszynski MH et al (1990) Nerve growth factor infusion in the primate brain reduces lesion-induced cholinergic neuronal degeneration. J Neurosci 10:3604\u20133614","journal-title":"J Neurosci"},{"key":"4_CR140","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/ana.410300502","volume":"30","author":"MH Tuszynski","year":"1991","unstructured":"Tuszynski MH et al (1991) Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain. Ann Neurol: Official Journal of the American Neurological Association and the Child Neurology Society 30:625\u2013636","journal-title":"Ann Neurol: Official Journal of the American Neurological Association and the Child Neurology Society"},{"key":"4_CR141","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nm1239","volume":"11","author":"MH Tuszynski","year":"2005","unstructured":"Tuszynski MH et al (2005) A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 11:551\u2013555","journal-title":"Nat Med"},{"key":"4_CR142","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1001\/jamaneurol.2015.1807","volume":"72","author":"MH Tuszynski","year":"2015","unstructured":"Tuszynski MH et al (2015) Nerve growth factor gene therapy: activation of neuronal responses in Alzheimer disease. JAMA Neurol 72:1139\u20131147","journal-title":"JAMA Neurol"},{"key":"4_CR143","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/j.1471-4159.2012.07900.x","volume":"123","author":"I Van Hove","year":"2012","unstructured":"Van Hove I et al (2012) Matrix metalloproteinase-3 in the central nervous system: a look on the bright side. J Neurochem 123:203\u2013216","journal-title":"J Neurochem"},{"key":"4_CR144","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/0306-4522(94)90285-2","volume":"59","author":"J Venero","year":"1994","unstructured":"Venero J et al (1994) Expression of neurotrophin and trk receptor genes in adult rats with fimbria transections: effect of intraventricular nerve growth factor and brain-derived neurotrophic factor administration. Neuroscience 59:797\u2013815","journal-title":"Neuroscience"},{"key":"4_CR145","doi-asserted-by":"publisher","first-page":"6844","DOI":"10.1073\/pnas.1914593117","volume":"117","author":"LA Welikovitch","year":"2020","unstructured":"Welikovitch LA et al (2020) Early intraneuronal amyloid triggers neuron-derived inflammatory signaling in APP transgenic rats and human brain. Proc Natl Acad Sci 117:6844\u20136854","journal-title":"Proc Natl Acad Sci"},{"key":"4_CR146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-019-0795-2","volume":"7","author":"CD Whelan","year":"2019","unstructured":"Whelan CD et al (2019) Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer\u2019s disease. Acta Neuropathol Commun 7:1\u201314","journal-title":"Acta Neuropathol Commun"},{"key":"4_CR147","doi-asserted-by":"publisher","first-page":"24566","DOI":"10.1074\/jbc.M602440200","volume":"281","author":"P Yan","year":"2006","unstructured":"Yan P et al (2006) Matrix metalloproteinase-9 degrades amyloid-\u03b2 fibrils in vitro and compact plaques in situ. J Biol Chem 281:24566\u201324574","journal-title":"J Biol Chem"},{"key":"4_CR148","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1515\/fhep-2014-0013","volume":"18","author":"J Zissimopoulos","year":"2015","unstructured":"Zissimopoulos J et al (2015) The value of delaying Alzheimer\u2019s disease onset. Forum Health Econ Policy 18:25\u201339. De Gruyter","journal-title":"Forum Health Econ Policy"}],"container-title":["Advances in Experimental Medicine and Biology","Recent Advances in NGF and Related Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-74046-7_4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T19:03:25Z","timestamp":1630091005000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-030-74046-7_4"}},"subtitle":["NGF Pathway Biomarkers and Drug Targets"],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9783030740450","9783030740467"],"references-count":148,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-74046-7_4","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"28 August 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}